JPRN-jRCTs031190010已完成未知
Alternation in glucagon secretion by dietary intake after administration of sodium glucose transporter-2 inhibitor. - Alternation in glucagon secretion by Sodium glucose transporter-2 inhibitor
Ichikawa Raishi0 个研究点目标入组 20 人开始时间: 2019年4月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
It has been suggested that SGLT-2 inhibitors may act directly on pancreatic alpha cells to increase glucagon secretion, so we hypothesized that SGLT-2 inhibitors contribute to improved glycemic control by altering glucagon secretion. To test this hypothesis, we conducted meal tolerance test before and after administrated SGLT-2 inhibitors in adult type 2 diabetes patients who managed with diet and exercise to determine whether glucagon secretion changed after food intake. For further validation, we also exa
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •Type 2 (non-insulin dependent) diabetes patients, aged 20 to 79, who are controlled in diet and exercise, and glycated Hb(HbA1c) is 7.0% or above and 10.0% or below.
排除标准
- •1. A patient suffering from acute disease
- •2. In case of malignacy
- •3. Renal dysfunction (estimeted GFR <60ml/min)
- •4. Liver dysfunction (AST >100U/l, ALT >100U/l)
- •5. Pregnant or possibility of pregnant
- •6. Lactating mothers
- •7. A patient suffering from endocrine disorders
- •8. A patient administrated any drugs affect glucose metabolism
- •9. Diabetic patients who have taken any hypoglycemic agents include SGLT-2 inhibitor in proximate 6 months
- •10.A patient undergoing or having history of treatment for ischemic heart disease
- •11.Chronic heart failure (NYHA class 2 or worse)
- •12.A patient undergoing or having history of treatment for cerebro-vascular disease
- •13.A patient undergoing or multiple (3 times or more) history of urinary or genital tract infection
- •14.A patient accompanied with severe diabetic retinopathy, nephropathy, neuropathy
- •15.A patient in hyperglycemic crisis or accompanied with marked symptom of hyperglycemia
- •16.Taking diuretics
- •17.Correspond to contraindication of Luseogliflozin
研究者
相似试验
已完成
4 期
Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 DiabeticsInsulin SecretionInsulin ResistanceNCT01610154Guangwei Li85
已完成
不适用
A study on the efficacy and biogenic adaptability affected by ipraglifloziType 2 diabetesJPRN-UMIN000015478Kobe University104
已完成
2 期
Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DMDiabetes Mellitus, Type 1NCT00515801University Hospital, Basel, Switzerland18
已完成
3 期
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient SettingType1 Diabetes MellitusNCT03979352Samuel Lunenfeld Research Institute, Mount Sinai Hospital28
已完成
不适用
Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic SteatosisNon-Alcoholic Fatty Liver DiseaseGlucagon ResistanceObesityType 1 DiabetesNCT04907721University of Copenhagen65